Keros Stock Based Compensation from 2010 to 2025

KROS Stock

USD 11.41 0.55 5.06%

Keros Therapeutics Stock Based Compensation yearly trend continues to be comparatively stable with very little volatility. Stock Based Compensation is likely to outpace its year average in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2019-03-31

Previous Quarter

8.8 M

Current Value

8.8 M

Quarterly Volatility

3.1 M

Covid

Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 7.3 K, Dividend Yield of 0.0 or PTB Ratio of 3.85. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.

Check out the analysis of Keros Therapeutics Correlation against competitors.

For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Latest Keros Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Keros Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Keros Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Keros Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

Keros Stock Based Compensation Regression Statistics

	Arithmetic Mean	8,241,298
	Geometric Mean	597,310
	Coefficient Of Variation	158.03
	Mean Deviation	10,721,160
	Median	81,000
	Standard Deviation	13,023,720
	Sample Variance	169.6T
	Range	34.7M
	R-Value	0.82
	Mean Square Error	58.3T
	R-Squared	0.68
	Significance	0.000086
	Slope	2,254,589
	Total Sum of Squares	2544.3T

Keros Stock Based Compensation History

	2025	34.7 M
	2024	33.1 M
	2023	28.8 M
	2022	18.7 M
	2021	11.7 M
	2020	4.1 M
	2019	59 K

Other Fundumenentals of Keros Therapeutics

Stock Based Compensation To Revenue

Keros Therapeutics Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.99	0.59	-0.96	-0.9	0.94	0.86	0.86	0.95	0.7	1.0	1.0	-0.83	1.0	0.87	0.91	0.77	0.23	-0.4
Total Stockholder Equity	1.0		0.99	0.56	-0.97	-0.88	0.93	0.87	0.87	0.95	0.68	1.0	1.0	-0.84	1.0	0.88	0.91	0.75	0.25	-0.4
Net Tangible Assets	0.99	0.99		0.5	-0.97	-0.83	0.9	0.87	0.87	0.93	0.61	0.99	0.99	-0.85	0.99	0.9	0.87	0.7	0.3	-0.34
Current Deferred Revenue	0.59	0.56	0.5		-0.59	-0.8	0.56	0.24	0.24	0.69	0.96	0.54	0.57	-0.26	0.55	0.33	0.5	0.56	-0.17	-0.66
Net Debt	-0.96	-0.97	-0.97	-0.59		0.9	-0.88	-0.82	-0.82	-0.98	-0.71	-0.97	-0.97	0.85	-0.97	-0.87	-0.86	-0.7	-0.23	0.51
Retained Earnings	-0.9	-0.88	-0.83	-0.8	0.9		-0.92	-0.73	-0.73	-0.94	-0.91	-0.88	-0.89	0.75	-0.88	-0.73	-0.89	-0.82	-0.07	0.62
Accounts Payable	0.94	0.93	0.9	0.56	-0.88	-0.92		0.89	0.89	0.9	0.72	0.94	0.93	-0.85	0.93	0.85	0.98	0.85	0.26	-0.43
Long Term Debt	0.86	0.87	0.87	0.24	-0.82	-0.73	0.89		1.0	0.81	0.44	0.88	0.86	-0.97	0.87	0.85	0.92	0.81	0.29	-0.3
Long Term Debt Total	0.86	0.87	0.87	0.24	-0.82	-0.73	0.89	1.0		0.81	0.44	0.88	0.86	-0.97	0.87	0.85	0.92	0.81	0.29	-0.3
Capital Surpluse	0.95	0.95	0.93	0.69	-0.98	-0.94	0.9	0.81	0.81		0.8	0.95	0.95	-0.85	0.95	0.86	0.87	0.76	0.21	-0.62
Total Liab	0.7	0.68	0.61	0.96	-0.71	-0.91	0.72	0.44	0.44	0.8		0.67	0.69	-0.47	0.67	0.47	0.69	0.71	-0.13	-0.75
Net Invested Capital	1.0	1.0	0.99	0.54	-0.97	-0.88	0.94	0.88	0.88	0.95	0.67		1.0	-0.86	1.0	0.89	0.92	0.76	0.25	-0.4
Total Current Assets	1.0	1.0	0.99	0.57	-0.97	-0.89	0.93	0.86	0.86	0.95	0.69	1.0		-0.83	1.0	0.88	0.91	0.75	0.24	-0.4
Capital Stock	-0.83	-0.84	-0.85	-0.26	0.85	0.75	-0.85	-0.97	-0.97	-0.85	-0.47	-0.86	-0.83		-0.84	-0.86	-0.88	-0.77	-0.29	0.4
Net Working Capital	1.0	1.0	0.99	0.55	-0.97	-0.88	0.93	0.87	0.87	0.95	0.67	1.0	1.0	-0.84		0.88	0.91	0.75	0.25	-0.4
Short Term Debt	0.87	0.88	0.9	0.33	-0.87	-0.73	0.85	0.85	0.85	0.86	0.47	0.89	0.88	-0.86	0.88		0.8	0.53	0.65	-0.35
Common Stock	0.91	0.91	0.87	0.5	-0.86	-0.89	0.98	0.92	0.92	0.87	0.69	0.92	0.91	-0.88	0.91	0.8		0.9	0.15	-0.47
Property Plant Equipment	0.77	0.75	0.7	0.56	-0.7	-0.82	0.85	0.81	0.81	0.76	0.71	0.76	0.75	-0.77	0.75	0.53	0.9		-0.2	-0.45
Net Receivables	0.23	0.25	0.3	-0.17	-0.23	-0.07	0.26	0.29	0.29	0.21	-0.13	0.25	0.24	-0.29	0.25	0.65	0.15	-0.2		0.07
Deferred Long Term Liab	-0.4	-0.4	-0.34	-0.66	0.51	0.62	-0.43	-0.3	-0.3	-0.62	-0.75	-0.4	-0.4	0.4	-0.4	-0.35	-0.47	-0.45	0.07

Click cells to compare fundamentals

About Keros Therapeutics Financial Statements

Keros Therapeutics shareholders use historical fundamental indicators, such as Stock Based Compensation, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Stock Based Compensation	33.1 M	34.7 M
Stock Based Compensation To Revenue	171.44	180.01

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Keros Stock Based Compensation from 2010 to 2025

Latest Keros Therapeutics' Stock Based Compensation Growth Pattern

Keros Stock Based Compensation Regression Statistics

Keros Stock Based Compensation History

Other Fundumenentals of Keros Therapeutics

Keros Therapeutics Stock Based Compensation component correlations

About Keros Therapeutics Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Keros Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY